The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia-Reference-Cited by-同舟云学术

The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia

Published:2015-05 Issue:5 Volume:169 Page:736-742.e1
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Hovingh G. Kees,Smits Loek P.,Stefanutti Claudia,Soran Handrean,Kwok See,de Graaf Jacqueline,Gaudet Daniel,Keyserling Constance H.,Klepp Heather,Frick Jennifer,Paolini John F.,Dasseux Jean-Louis,Kastelein John J.P.,Stroes Erik S.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference34 articles.

1. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome;Sjouke;Eur Heart J,2014

2. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia;Goldstein;J Clin Invest,1973

3. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy;Raal;Circulation,2011

4. Plasmapheresis in familial hypercholesterolemia;Thompson;Arteriosclerosis,1989

5. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibiti;Raal;Circulation,2012

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-density lipoprotein infusion therapy: A review;Journal of Clinical Lipidology;2024-05

2. A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease;Pharmaceutics;2023-05-15

3. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction;European Heart Journal - Cardiovascular Pharmacotherapy;2023-02-14

4. Very low HDL levels: clinical assessment and management;Archives of Endocrinology and Metabolism;2023-01-18

5. Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics;Cardiovascular Endocrinology and Metabolism;2023